The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, sa.1, ss.8-14, 2012 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 22 Sayı: 1
- Basım Tarihi: 2012
- Doi Numarası: 10.4999/uhod.12004
- Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.8-14
- Anahtar Kelimeler: Chronic myeloid leukemia, Dasatinib, Treatment dosage, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITOR, NILOTINIB FORMERLY AMN107, CHRONIC-PHASE, BCR-ABL, IMATINIB RESISTANCE, THERAPY, FAILURE, NONADHERENCE, INTOLERANCE
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Ondokuz Mayıs Üniversitesi Adresli: Evet
Özet
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.